Mirum Pharmaceuticals

Mirum Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing treatments for rare diseases, especially rare liver and cholestatic conditions. Its marketed products include LIVMARLI (maralixibat) for cholestatic pruritus in Alagille syndrome and PFIC, and CHOLBAM (cholic acid) and CTEXLI (chenodiol) for bile acid synthesis disorders and cerebrotendinous xanthomatosis. The company is also advancing a pipeline that includes volixibat.